Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005

NCT04677972 is registered in ClinicalTrials.gov with Sound Pharmaceuticals, Incorporated as lead sponsor.

NCT NCT04677972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04677972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005
Lead sponsor
Sound Pharmaceuticals, Incorporated
Phase
Phase 3
Overall status
Completed
Start date
August 2, 2022
Completion date
July 25, 2024
Enrollment
220 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

meniere disease, ménière